Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors☆
References (25)
- et al.
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
J Am Coll Cardiol
(1986) - et al.
Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men
Lancet
(1986) - et al.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, I: a dose-response study
Atherosclerosis
(1990) - et al.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, II: once-daily versus twice-daily dosing
Atherosclerosis
(1990) Might treatment of hypercholesterolemia increase non-cardiac mortality
Lancet
(1991)- et al.
Platelet activation by plasma lipoproteins
Prog Cardiovasc Dis
(1987) - et al.
Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia
Lancet
(1982) - et al.
Abnormalities of blood rheology in familial hypercholesterolemia: effects of treatment
Atherosclerosis
(1990) - et al.
Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients
Atherosclerosis
(1989) - et al.
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
N Engl J Med
(1987)
Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study
Ann Intern Med
(1971)
The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease
JAMA
(1984)
Cited by (0)
- ☆
This study was supported by a grant from Bristol-Myers Squibb Company, Princeton, New Jersey.
- ∗
See Appendix for the list of participants.
Copyright © 1993 Published by Elsevier Inc.